RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: news

Antibody Startup Emerges from Stealth: Cell Surface Bio Set to Transform the $10B Antibody Reagent Market

Company debuts catalog of validated, recombinant, specific antibodies against difficult protein targets, providing only the highest quality reagents for life sciences research

A scientist at Cell Surface Bio describing confocal immunofluorescence data obtained using a CSB antibody.

Philadelphia – Emerging from stealth mode today, Cell Surface Bio (CSB) launches VeRSaMAb research antibodies with the vision of delivering “antibodies that always work,” answering the call of the scientific community for reliable reagents with uncompromising quality. Providing monoclonal antibodies that are extensively validated, recombinantly cloned, and exquisitely specific, CSB is being built to transform the >$10 billion antibody reagent market where currently half of the antibodies sold do not work as designed.

View Cell Surface Bio’s mission and the VeRSaMAb catalog

Validated Antibodies with Unparalleled Specificity

VeRSaMAbs are produced at CSB and extensively characterized to ensure reliable results in customers’ experiments every time. Now available for purchase, VeRSaMAbs are:

  • Validated for flow cytometry, immunofluorescence, and other applications
  • Recombinantly cloned for batch-to-batch consistency, enhanced detection, and reproducible results
  • Specific for only the target of interest as assessed across 6,000 native proteins of the Membrane Proteome Array™

Transforming Life Science Reagents

“Cell Surface Bio was created by scientists for scientists,” explained Benjamin Doranz, PhD, Co-founder of Cell Surface Bio. “Every researcher I’ve met, myself included, knows the frustration of time wasted in the lab running experiments with antibodies that simply do not work. Our goal is to provide researchers with only the highest quality monoclonal antibodies that are fully validated and engineered for the highest sensitivity of detection, so that they always work in our customers’ experiments.”

A spin-out of Philadelphia’s Integral Molecular, CSB leverages the parent company’s 20+ years of expertise developing and characterizing therapeutic antibodies that target complex and conserved proteins on the cell surface. CSB’s VeRSaMAbs are derived using the same next-generation platform used to isolate best-in-class drugs, featuring high-throughput mRNA immunization, Lipoparticles™ (virus-like particles) for high-concentration presentation of structurally intact membrane proteins, divergent species (chickens) to generate antibodies against conserved epitopes, and optimized protocols for the isolation of rare antibodies, even for membrane proteins embedded in a lipid bilayer.

VeRSaMAbs are available for a wide range of protein targets across scientific fields, including immunology, oncology, and virology, and CSB’s catalog will continue to expand as MAbs are validated. Visit CSB to suggest new antibodies to add to the catalog!

About Cell Surface Bio
Cell Surface Bio’s mission is to provide researchers with only the highest quality antibodies, because as fellow scientists, we know that your time in the lab is valuable. CSB’s VeRSaMAb antibodies are built on 20+ of expertise in discovering and characterizing antibodies against the most difficult cell surface proteins. VeRSaMAbs are Validated, Recombinant, and Specific to ensure reliable results every time.

Press Contact:
Soma Banik, PhD, Director of Public Relations
Cell Surface Bio
215-987-0728
cellsurfacebio.com

Follow CSB on LinkedIn

Webinar presented by Integral Molecular and Fierce Biotech – Redefining Antibody Specificity Profiling for IND

Thursday, June 6, 2024
8 am PT, 11 am ET, 17:00 CET
Register now

Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods, such as tissue cross-reactivity studies, are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. So, what are the alternatives?

Join our webinar to learn about the new, innovative cell-based protein array approach to specificity profiling. We’ll take a deep dive into the Membrane Proteome Array (MPA), a 6,000-protein array platform that tests binding of biotherapeutics across the full human membrane proteome expressed in unfixed cells.

Attendees will learn how:

  • Integral Molecular’s MPA is used to rapidly and accurately identify potential off-target binding liabilities
  • MPA data support both lead selection and IND submissions with advantages over tissue cross-reactivity studies
  • Cell protein arrays, like the MPA, are rapidly progressing towards FDA endorsement through inclusion in CAR-T development guidelines and qualification as an antibody Drug Development Tool
 Integral Molecular and Fierce webinar 2024

Register now

Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery

Researchers can now access Integral Molecular’s antibody testing expertise alongside its extensive collection of virus-like reagents including reporter viruses, VLPs, and pseudoviruses to acquire critical neutralization data.

Philadelphia – Integral Molecular, a leader in providing safe research reagents for virology, announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.

Learn more about Integral Molecular’s Neutralization Assay Services

With over 20 years’ experience in virology, Integral Molecular has developed innovative solutions that enable researchers to study viruses safely and efficiently. These solutions include Reporter Virus Particles (RVPs), pseudoviruses, virus-like particles (VLPs), and Influenza TiterSafe VLPs for hemagglutination assays. These virus-like reagents cannot replicate and are incapable of causing infectious disease, enabling the study of even the most pathogenic viruses in a standard laboratory environment.

Integral Molecular’s Neutralization Assay Services enable diverse applications:

  • Neutralization profiling for antibodies targeting viral proteins. Studies employ RVPs including coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV), influenza, Zika, dengue, yellow fever, or custom reporter viruses. RVPs are produced using ISO 9001 certified processes that enable generation of reproducible, reliable data.
  • Neutralization experiments can be conducted for monoclonal antibodies or preclinical sera using the company’s catalog of 100+ reporter viruses or custom variants with specified mutations.
  • Antibody cocktail screening to test neutralization with antibody combinations.

“Our virus research tools have been instrumental in laboratories worldwide, providing safe alternatives to live viruses,” said Maya Cabot, PhD, Senior Product Manager at Integral Molecular. “Given the limited access to dedicated containment facilities for manipulating pathogenic materials, our Neutralization Assay Services provide vital support to diverse researchers, especially benefiting smaller companies with limited laboratory infrastructure.”

Integral Molecular’s virology research tools have been adopted by over 100 laboratories worldwide and featured in over 250 publications.

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in creating and commercializing transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on membrane proteins, viruses, and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Public Relations
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Webinar presented by Integral Molecular and The Antibody Society – Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets

Thursday, April 25, 2024
8 am PT, 11 am ET, 17:00 CET
View the recording

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development.

In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success

Antibody Society and Integral Molecular webinar

View the recording

Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service

ISO 9001 certification validates Integral Molecular’s quality processes for its Membrane Proteome Array, reflecting the company’s commitment to quality.

Philadelphia – Integral Molecular, a leader in antibody discovery and characterization, proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ (MPA) specificity testing services. This platform is a vital tool for biotechnology and pharmaceutical companies to assess the safety and off-target reactivity of therapeutic antibodies and other biologics.

Despite their reputation for ‘exquisite specificity’, antibodies and antibody-based therapies, such as CAR-T cells, frequently demonstrate unexpected off-target binding. The MPA utilizes its collection of over 6,000 native-conformation membrane proteins that encompass nearly the entire human membrane proteome to de-risk therapeutics and reveal unintended off-target liabilities early in drug development.

Learn more about the Membrane Proteome Array™

ISO 9001 is a globally recognized standard for quality management systems (QMS) that encompass process controls, comprehensive documentation, plans for corrective action, and continuous improvement.

“Integral Molecular has maintained a culture of commitment to delivering exceptional quality products and services for over 20 years. As the industry increasingly relies on MPA specificity profiling to support drug safety, we are delighted to receive ISO 9001 Certification to reinforce our commitment to quality for our customers.”

-Rachel Fong, Director of Sales and Alliances, Integral Molecular

With the ability to pinpoint the identity of unanticipated protein interactions that could pose safety consequences, the MPA was accepted by the FDA to participate in the agency’s ISTAND program to qualify new drug development tools for IND, NDA, or BLA applications. The MPA qualification plan was submitted to the FDA in 2023 and is currently under review.

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in creating and commercializing transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on membrane proteins, viruses, and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Public Relations
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Enters Into Exclusive Antibody License With Seismic Therapeutic

Philadelphia – Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets, announced today that it has entered into an antibody license agreement with Seismic Therapeutic. Under the terms of the agreement, Integral Molecular will provide an exclusive license to Seismic Therapeutic for a collection of fully humanized, highly specific, preclinical antibodies to add to their platform, library, and pipeline of molecules in the immunology space. Seismic Therapeutic will assume full responsibility for all research, development, and commercialization activities related to these antibodies.

The antibodies licensed by Seismic Therapeutic were identified using Integral Molecular’s MPS Antibody Discovery platform. This platform is built upon the company’s 20+ years of experience in working with the most challenging protein targets and ability to deliver preclinical lead candidate molecules. Unique aspects of this platform include the use of advanced immunization strategies including combinations of RNA, DNA and protein boosting via Lipoparticles, and evolutionarily divergent host animals (chickens) capable of generating diverse panels of antibodies against highly conserved targets.

“We are thrilled that Seismic chose Integral Molecular as a partner for their antibody discovery efforts,” said Ross Chambers, PhD, VP of Antibody Discovery at Integral Molecular. “Using chickens as immunization hosts was important for Seismic’s project, as conventional approaches like mouse immunization would not have produced the diverse antibodies needed for their program. We wish Seismic Therapeutic much success as they continue to develop these antibodies.”

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 500 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com, and follow us on LinkedIn and on X (formerly Twitter) @Seismic_Tx.

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Public Relations
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing
Non-infectious TiterSafe particles can be used as a virus substitute in hemagglutination inhibition (HAI) assays to test influenza vaccine efficacy.
Non-infectious TiterSafe particles can be used as a virus substitute in hemagglutination inhibition (HAI) assays to test influenza vaccine efficacy.

Philadelphia – Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles, an off-the-shelf virus-alternative for key experiments in testing influenza vaccines. Titersafe is a safe and convenient substitute for live virus that is ready for immediate use, reduces biosafety hazards for lab workers, and is well-suited for high-throughput assays. In contrast, traditional assays require the difficult preparation of live influenza virus, potentially expose researchers to infection, and need dedicated containment facilities for pandemic virus strains.

TiterSafe particles mimic the architecture of live virus, featuring surface influenza proteins hemagglutinin (HA) and neuraminidase (NA) along with an interior protein core. Crucially, they lack DNA or RNA components that enable virus replication. The HA protein on TiterSafe particles behaves identically to HA on live virus in experiments, sticking to red blood cells and causing them to clump, or “hemagglutinate”. Inhibition of this clumping by anti-HA antibodies in serum (an “HAI assay”) is the standard FDA-accepted method for influenza vaccine assessment. TiterSafe comes in assay-ready portions for immediate use in HAI assays and is available with HA and NA variants to match seasonal strains of influenza.

“For over 20 years we have responded to viral threats including SARS-CoV-2, dengue, Zika, and now influenza by developing products that allow any lab to work safely with viruses,” said Kyle Doolan, Director of R&D at Integral Molecular. “While the FDA-accepted HAI assay is relatively easy to perform, scaling up reagents and working with highly infectious live viruses requires considerable time and resources. We are pleased to offer this off-the-shelf reagent that will enable vaccine developers to focus their time on more pressing research.”

TiterSafe is currently available for seasonal and pandemic influenza strains. Additional products will be released as new strains are announced.

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 500 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Public Relations
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

Philadelphia – Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets will present multispecific molecules targeting GPRC5D, BCMA, and CD3 this week during the Society for Immunotherapy of Cancer (SITC) conference in San Diego.

Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients. A trispecific antibody that simultaneously engages these molecules while activating T cells is expected to provide comparable and additional benefits as a monotherapy.

Integral Molecular’s oncology drug discovery program has yielded a panel of high affinity bispecific and trispecific molecules targeting GPRC5D, a GPCR target with complex structural biology. The molecules show picomolar cell-killing activity and are highly selective for their targets.

“For decades we have navigated the complexities of molecules like GPRC5D, successfully discovering antibodies against even the most challenging targets,” said Joseph Rucker, PhD, VP of R&D at Integral Molecular. “In just a few short months we were able to simultaneously target GPRC5D and BCMA, and we expect to rapidly advance this molecule into preclinical studies.”

The company leveraged its MPS antibody discovery platform to discover and engineer antibodies for this program. MPS is unique from other platforms in the use of RNA, DNA, and virus-like particles (VLPs, or Lipoparticles) to present properly folded membrane proteins, and the use of divergent species (chickens) to generate diverse antibody responses.

Dr. Rucker will present the company’s bi- and trispecific GPRC5D antibodies in a poster during the SITC 2023 conference. GPRC5D and other antibody assets from Integral Molecular are available for licensing.

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 500 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Public Relations
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Secures Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets

PHILADELPHIA–Integral Molecular, a leading biotech company specializing in antibody discovery against challenging protein targets, announces that it has been awarded NIH funding totaling $896,000. The NIH has identified 230 GPCRs and ion channels as underexplored targets with potential to impact human health as part of its project, Illuminating the Druggable Genome. Funding awarded by NIH enables Integral Molecular to discover antibodies against many of these targets. To enable better models of human disease, Integral Molecular has also received NIH funding to discover antibodies that target highly conserved proteins across species.

Integral Molecular will employ its MPS antibody discovery platform to discover antibodies for both initiatives. This platform is tailored to deliver molecules against difficult and conserved targets such as GPCRs and ion channels that are valuable drug targets. Integral Molecular’s strategy of generating antibodies in chickens is key for producing antibodies against conserved targets, a feat not easily achieved with conventional technologies. What additionally sets MPS apart from other platforms is the use of RNA and virus-like particles (VLPs, or Lipoparticles) for presenting properly folded membrane proteins to generate robust responses.

“With our decades-long experience studying complex proteins and an antibody success rate exceeding 95%, we are confident in delivering the desired molecules,” stated Ross Chambers, PhD, Vice President of Antibody Discovery at Integral Molecular. “Our isolation of antibodies reactive with diverse species will help reduce the use of non-human primates in research.”

Integral Molecular scientists will present the company’s antibody discovery strategies during the upcoming SITC conference. They will also describe the company’s pipeline featuring antibodies targeting claudin 6 and GPRC5D for multiple myeloma and other cancers.

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 500 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Follow Integral Molecular on LinkedIn
Follow Integral Molecular on Twitter

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Public Relations
215-966-6061
info@integralmolecular.com
www.integralmolecular.com